Argenx price target raised to $1,040 from $766 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,040 from $766 and keeps an Overweight rating on the shares. The firm’s model now incorporates six new pipeline indications for Vyvgart and one new pipeline indication for empasiprubart, capturing an opportunity it sees being “underappreciated” by the Street, the analyst tells investors.